2026-04-13T05:58:48Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1625232025-12-04T21:40:34Zcom_2072_1057col_2072_478917col_2072_478933

00925njm 22002777a 4500 dc Arranz Gibert, Pol author Guixer, Bernat author Prades, Roger author Ciudad Fernández, Sonia author Giralt Lledó, Ernest author Teixidó Turà, Meritxell author 2020-05-26T21:54:36Z 2020-05-26T21:54:36Z 2019-03-19 2020-05-26T21:54:37Z In recent decades, peptide blood-brain barrier shuttles have emerged as a promising solution for brain drugs that are not able to enter this organ. The research and development of these compounds involve the use of in vitro cell-based models of the BBB. Nevertheless, peptide transport quantification implies the use of large amounts of peptide (upper micromolar range for RP-HPLC-PDA) or of derivatives (e.g. fluorophore or quantum-dot attachment, radiolabeling) in the donor compartment in order to enhance the detection of these molecules in the acceptor well, although their structure is highly modified. Therefore, these methodologies either hamper the use of low peptide concentrations, thus hindering mechanistic studies, or do not allow the use of the unmodified peptide. Here we successfully applied a MALDI-TOF MS methodology for transport quantification in an in vitro BBB cell-based model. A light version of the acetylated peptide was evaluated, and the transport was subsequently quantified using a heavy internal standard (isotopically acetylated). We propose that this MALDI-TOF MS approach could also be applied to study the transport across other biological barriers using the appropriate in vitro transport models (e.g. Caco-2, PAMPA). Pèptids Barrera hematoencefàlica Cervell Peptides Blood-brain barrier Brain A MALDI-TOF-based method for studying the transport of BBB shuttles-enhancing sensitivity and versatility of cell-based in vitro transport models.